Endometrial Cancer Clinical Trials in Dresden
3 recruitingDresden, Germany
Showing 1–3 of 3 trials
Recruiting
Phase 3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
AstraZeneca600 enrolled249 locationsNCT06989112
Recruiting
Phase 3
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Endometrial CancerMalignant Solid Tumour
AstraZeneca700 enrolled294 locationsNCT07044336
Recruiting
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
Endometrial Cancer
AstraZeneca150 enrolled33 locationsNCT06890273